This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Google Scholar Articles by Maiolino, G. Articles by Rossi, G. P. PubMed PubMed Citation Articles by Maiolino, G. Articles by Rossi, G. P. Related Collections Cardiovascular Endocrinology

Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients

Division of Cardiology (M.Z., L.P.), Cittadella Hospital, 35013 Cittadella, Italy; and Department of Clinical and Experimental Medicine (G.M., M.C., D.S., K.A., A.C.P., G.P.R.), University of Padova, 35128 Padova, Italy

Address all correspondence and requests for reprints to: Professor Gian Paolo Rossi, M.D., F.A.C.C., F.A.H.A., Department of Clinical and Experimental Medicine, Clinica Medica 4, University Hospital, via Giustiniani, 2, 35128 Padova, Italy. E-mail: gianpaolo.rossi{at}unipd.it.

Context: The prognostic value of plasma levels of adiponectin, an adipocytokine with antiatherogenic, antiinflammatory, and insulin-sensitizing effects, is contentious.

Objective: The objective of the study was to investigate whether plasma adiponectin levels predict cardiovascular (CV) events and mortality in high-risk coronary artery disease (CAD) patients.

Design, Setting, Participants, and Main Outcome Measure: We measured plasma adiponectin and examined its impact on the incidence of CV deaths and events at follow-up in the context of all potentially relevant background covariates in 712 high-risk patients of the Genetic and ENvironmental factors in Coronary Atherosclerosis study who underwent coronary angiography for suspected CAD. Based on the population plasma adiponectin median (6.38 µg/ml, interquartile range 4.2–10.2), we split the patients in a high- and a low-plasma adiponectin subgroup. After a median follow-up of 3.8 years (interquartile range 3.3–4.3 yr), outcome data were obtained in 100% of the patients and 45 CV deaths (6.4%) were recorded. Kaplan-Meier analysis unexpectedly showed a higher CV death rate in high-plasma adiponectin than low-plasma adiponectin patients. By contrast, multivariate Cox regression analysis, in which potential confounders, including ongoing medical treatment, were considered, showed no impact of plasma adiponectin on CV death. Similar negative results were obtained using the propensity score that considered all relevant covariables and medical treatment rate, which differed between the high- and low-plasma adiponectin group.

Conclusions: In high-risk CAD patients, plasma adiponectin above the median (6.38 µg/ml) implies a paradoxical higher risk of CV death. However, when relevant covariates that differ between high- and low-plasma adiponectin groups are considered, this association wanes, indicating that the clustering of plasma adiponectin with other covariates can abolish its impact on CV prognosis.

This article has been cited by other articles:

				M. Cesari and G. P. Rossi Adiponectin and prognostic outcome in patients with coronary artery disease Eur. Heart J., October 2, 2008; 29(20): 2578 - 2579. [Full Text] [PDF]